Summary & Overview

Kidney and Urinary Tract Neoplasms with CC: Inpatient Reimbursement Overview

DRG 687 covers kidney and urinary tract neoplasms with a Complication or Comorbidity, encompassing inpatient care for renal, ureteral, and bladder tumors that require additional resources. This Diagnosis-Related Group matters for inpatient reimbursement because the presence of a Complication or Comorbidity increases payment relative to non-Complication or Comorbidity cases to reflect higher expected resource use.

Kidney and Urinary Tract NeoplasmsDRG Kidney and Urinary Tract Neoplasms with CCDRG 687Diagnosis-Related GroupInpatient ReimbursementMedicareUrologyOncologyNephrectomyEndoscopic Procedures

DRG 687 Overview

DRG 687 covers inpatient admissions for kidney and urinary tract neoplasms with a Complication or Comorbidity present, including surgical and nonsurgical management of renal, ureteral, and bladder tumors when an associated complication or comorbidity affects care. This Diagnosis-Related Group groups cases with increased resource use compared with non-Complication or Comorbidity cases, influencing Medicare payment by adjusting relative weight for greater clinical complexity. Typical services include tumor resections, nephrectomy procedures, endoscopic interventions, and perioperative medical management tied to the neoplasm and the Complication or Comorbidity. Accurate clinical documentation and coding of the neoplasm type and any Complication or Comorbidity are essential for appropriate inpatient reimbursement under Medicare.

Clinical Trials

Perioperative and surgical technique trials assessing nephron-sparing surgery versus radical nephrectomy in patients with localized kidney tumors and comorbid conditions: these studies enroll inpatients with kidney neoplasms who face competing risks from chronic kidney disease, diabetes, or cardiovascular disease to compare short-term surgical morbidity, length of stay, blood loss, and early renal function outcomes. They address which operative approach minimizes inpatient complications and resource use, directly informing hospital care pathways and reimbursement considerations for patients classified under this DRG.
Neoadjuvant and adjuvant therapy feasibility and sequencing studies in patients with high-risk or locally advanced urinary tract neoplasms undergoing inpatient surgical care: trials in this category examine timing, tolerability, and perioperative safety of systemic therapies given before or after definitive surgery in patients with comorbidities that complicate inpatient management. Findings help providers optimize inpatient timing of systemic treatments relative to surgery and guide payers on expected inpatient resource utilization and readmission risk associated with multimodal care.
Post-discharge outcomes, surveillance, and care coordination studies focused on renal function preservation and readmission prevention for patients after inpatient treatment for kidney and urinary tract neoplasms: these observational and interventional studies enroll patients discharged after nephrectomy or urinary tract surgery to evaluate care transitions, outpatient surveillance strategies, and interventions (e.g., early nephrology follow-up, medication reconciliation) that reduce 30- and 90-day readmissions, progression to end-stage renal disease, and unplanned costs. This research is relevant to hospitals and payers because improvements in post-discharge management can lower avoidable inpatient utilization, improve long-term costs, and enhance risk adjustment for patients in this DRG.

Related Codes

654-MAJOR-BLADDER-PROCEDURES-WITH-CC

Major Bladder Procedures with CC: Inpatient Reimbursement Overview

666-PROSTATECTOMY-WITH-CC

Prostatectomy with CC: Inpatient Reimbursement Overview

655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

670-TRANSURETHRAL-PROCEDURES-WITHOUT-CC-MCC

Transurethral Procedures without CC/MCC: Inpatient Reimbursement Overview

667-PROSTATECTOMY-WITHOUT-CC-MCC

Prostatectomy without CC/MCC: Inpatient Reimbursement Overview

662-MINOR-BLADDER-PROCEDURES-WITH-MCC

Minor Bladder Procedures with MCC: Inpatient Reimbursement Overview

660-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-CC

Kidney and Ureter Procedures for Non-Neoplasm with CC: Inpatient Reimbursement Overview

651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

661-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITHOUT-CC-MCC

Kidney and Ureter Procedures for Non-Neoplasm without CC/MCC: Inpatient Reimbursement Overview

Showing 1–10 of 41

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.